{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T01:43:27Z","timestamp":1768268607895,"version":"3.49.0"},"reference-count":44,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,8,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Forodesine and nelarabine (the pro-drug of ara-G) are 2 nucleoside analogues with promising anti-leukemic activity. To better understand which pediatric patients might benefit from forodesine or nelarabine (ara-G) therapy, we investigated the in vitro sensitivity to these drugs in 96 diagnostic pediatric leukemia patient samples and the mRNA expression levels of different enzymes involved in nucleoside metabolism. Forodesine and ara-G cytotoxicities were higher in T-cell acute lymphoblastic leukemia (T-ALL) samples than in B-cell precursor (BCP)\u2013ALL and acute myeloid leukemia (AML) samples. Resistance to forodesine did not preclude ara-G sensitivity and vice versa, indicating that both drugs rely on different resistance mechanisms. Differences in sensitivity could be partly explained by significantly higher accumulation of intracellular dGTP in forodesine-sensitive samples compared with resistant samples, and higher mRNA levels of dGK but not dCK. The mRNA levels of the transporters ENT1 and ENT2 were higher in ara-G\u2013sensitive than \u2013resistant samples. We conclude that especially T-ALL, but also BCP-ALL, pediatric patients may benefit from forodesine or nelarabine (ara-G) treatment.<\/jats:p>","DOI":"10.1182\/blood-2011-02-337840","type":"journal-article","created":{"date-parts":[[2011,7,6]],"date-time":"2011-07-06T00:56:19Z","timestamp":1309913779000},"page":"2184-2190","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":40,"title":["In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia"],"prefix":"10.1182","volume":"118","author":[{"given":"Irene","family":"Homminga","sequence":"first","affiliation":[{"name":"Department of Pediatric Hemato-Oncology, Erasmus MC Rotterdam\u2013Sophia Children's Hospital, Rotterdam, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Michel","family":"Zwaan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hemato-Oncology, Erasmus MC Rotterdam\u2013Sophia Children's Hospital, Rotterdam, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal Y.","family":"Manz","sequence":"additional","affiliation":[{"name":"Mundipharma International Limited, Cambridge, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Parker","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, Biocryst Pharmaceutical Inc, Birmingham, AL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanta","family":"Bantia","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, Biocryst Pharmaceutical Inc, Birmingham, AL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem Korstiaan","family":"Smits","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hemato-Oncology, Erasmus MC Rotterdam\u2013Sophia Children's Hospital, Rotterdam, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Higginbotham","sequence":"additional","affiliation":[{"name":"Mundipharma International Limited, Cambridge, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Pieters","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hemato-Oncology, Erasmus MC Rotterdam\u2013Sophia Children's Hospital, Rotterdam, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jules P. P.","family":"Meijerink","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hemato-Oncology, Erasmus MC Rotterdam\u2013Sophia Children's Hospital, Rotterdam, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"2","key":"2019111808055659800_B1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia.","volume":"354","author":"Pui","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111808055659800_B2","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3324\/haematol.11203","article-title":"Pediatric acute myeloid leukemia: towards high-quality cure of all patients.","volume":"92","author":"Kaspers","year":"2007","journal-title":"Haematologica"},{"issue":"5","key":"2019111808055659800_B3","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","article-title":"Modern therapy of acute lymphoblastic leukemia.","volume":"29","author":"Bassan","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111808055659800_B4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","article-title":"Therapeutic advances in acute myeloid leukemia.","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111808055659800_B5","doi-asserted-by":"crossref","first-page":"8615","DOI":"10.1021\/bi980658d","article-title":"One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase.","volume":"37","author":"Miles","year":"1998","journal-title":"Biochemistry"},{"issue":"8","key":"2019111808055659800_B6","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1182\/blood-2009-02-207654","article-title":"Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.","volume":"114","author":"Alonso","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111808055659800_B7","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1567-5769(03)00076-6","article-title":"Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor\u2013BCX-1777.","volume":"3","author":"Bantia","year":"2003","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"2019111808055659800_B8","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1073\/pnas.071050798","article-title":"Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes.","volume":"98","author":"Kicska","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2019111808055659800_B9","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2006-03-007468","article-title":"Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.","volume":"108","author":"Balakrishnan","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2019111808055659800_B10","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1073\/pnas.76.5.2430","article-title":"Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines.","volume":"76","author":"Carson","year":"1979","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2019111808055659800_B11","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.1073\/pnas.74.12.5677","article-title":"Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s).","volume":"74","author":"Carson","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2019111808055659800_B12","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1172\/JCI109058","article-title":"Deoxyguanosine triphosphate as a possible toxic metabolite in the immunodeficiency associated with purine nucleoside phosphorylase deficiency.","volume":"61","author":"Cohen","year":"1978","journal-title":"J Clin Invest"},{"issue":"7914","key":"2019111808055659800_B13","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0140-6736(75)91950-9","article-title":"Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity.","volume":"1","author":"Giblett","year":"1975","journal-title":"Lancet"},{"issue":"4","key":"2019111808055659800_B14","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood.V61.4.660.bloodjournal614660","article-title":"Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells.","volume":"61","author":"Cohen","year":"1983","journal-title":"Blood"},{"issue":"8","key":"2019111808055659800_B15","first-page":"3646","article-title":"Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts.","volume":"45","author":"Verhoef","year":"1985","journal-title":"Cancer Res"},{"issue":"3","key":"2019111808055659800_B16","first-page":"1008","article-title":"Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts.","volume":"45","author":"Shewach","year":"1985","journal-title":"Cancer Res"},{"issue":"3","key":"2019111808055659800_B17","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1172\/JCI111514","article-title":"Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblasts.","volume":"74","author":"Ullman","year":"1984","journal-title":"J Clin Invest"},{"issue":"15","key":"2019111808055659800_B18","first-page":"3352","article-title":"2-amino-6-methoxypurine arabinoside: an agent for T-cell malignancies.","volume":"55","author":"Lambe","year":"1995","journal-title":"Cancer Res"},{"issue":"13","key":"2019111808055659800_B19","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2005-03-1309","article-title":"A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).","volume":"106","author":"Gandhi","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2019111808055659800_B20","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1182\/blood-2010-02-272039","article-title":"Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.","volume":"116","author":"Balakrishnan","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111808055659800_B21","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2217\/fon.10.83","article-title":"Forodesine: review of preclinical and clinical data.","volume":"6","author":"Al-Kali","year":"2010","journal-title":"Future Oncol"},{"issue":"12","key":"2019111808055659800_B22","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"issue":"15","key":"2019111808055659800_B23","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.","volume":"23","author":"Berg","year":"2005","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111808055659800_B24","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2005.03.199","article-title":"Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies.","volume":"23","author":"Kurtzberg","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111808055659800_B25","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood-2002-05-1600","article-title":"Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.","volume":"101","author":"Stam","year":"2003","journal-title":"Blood"},{"issue":"17","key":"2019111808055659800_B26","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2003.11.031","article-title":"Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.","volume":"21","author":"Den Boer","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111808055659800_B27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0003-2697(89)90420-X","article-title":"Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers.","volume":"180","author":"Sherman","year":"1989","journal-title":"Anal Biochem"},{"issue":"2","key":"2019111808055659800_B28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1525-1578(10)60652-6","article-title":"A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR.","volume":"3","author":"Meijerink","year":"2001","journal-title":"J Mol Diagn"},{"issue":"12","key":"2019111808055659800_B29","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/sj.bjc.6602881","article-title":"The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.","volume":"93","author":"Hubeek","year":"2005","journal-title":"Br J Cancer"},{"issue":"1","key":"2019111808055659800_B30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood.V99.1.245","article-title":"Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.","volume":"99","author":"Zwaan","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2019111808055659800_B31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pcl.2007.11.001","article-title":"Acute leukemias in children with Down syndrome.","volume":"55","author":"Zwaan","year":"2008","journal-title":"Pediatr Clin North Am"},{"issue":"6","key":"2019111808055659800_B32","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S1567-5769(01)00056-X","article-title":"Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)\u2013a novel potent and orally active immunosuppressive agent.","volume":"1","author":"Bantia","year":"2001","journal-title":"Int Immunopharmacol"},{"issue":"23","key":"2019111808055659800_B33","first-page":"6498","article-title":"Differential metabolism of 9-beta-D-arabinofuranosylguanine in human leukemic cells.","volume":"49","author":"Shewach","year":"1989","journal-title":"Cancer Res"},{"issue":"5","key":"2019111808055659800_B34","first-page":"375","article-title":"Adenosine deaminase and purine nucleoside phosphorylase in childhood lymphoblastic leukemia: relation with differentiation stage, in vitro drug resistance and clinical prognosis.","volume":"6","author":"Pieters","year":"1992","journal-title":"Leukemia"},{"issue":"1","key":"2019111808055659800_B35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1365-2141.1999.01509.x","article-title":"Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562.","volume":"106","author":"Dumontet","year":"1999","journal-title":"Br J Haematol"},{"issue":"8","key":"2019111808055659800_B36","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0145-2126(96)00170-1","article-title":"Deoxycytidine kinase mRNA levels in leukemia cells with competitive polymerase chain reaction assay.","volume":"20","author":"Kawasaki","year":"1996","journal-title":"Leuk Res"},{"issue":"9","key":"2019111808055659800_B37","first-page":"2389","article-title":"Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene.","volume":"52","author":"Owens","year":"1992","journal-title":"Cancer Res"},{"issue":"7","key":"2019111808055659800_B38","first-page":"1005","article-title":"Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2\u2032-deoxycytidine.","volume":"7","author":"Stegmann","year":"1993","journal-title":"Leukemia"},{"issue":"3\u20134","key":"2019111808055659800_B39","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/10428199809059234","article-title":"Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: decreased expression of dCK gene in relapsed leukemia.","volume":"31","author":"Kakihara","year":"1998","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019111808055659800_B40","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00001813-199706000-00015","article-title":"Deoxycytidine kinase mRNA expression in childhood acute lymphoblastic leukemia.","volume":"8","author":"Stammler","year":"1997","journal-title":"Anticancer Drugs"},{"issue":"11","key":"2019111808055659800_B41","first-page":"3100","article-title":"Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase.","volume":"62","author":"Rodriguez","year":"2002","journal-title":"Cancer Res"},{"issue":"2","key":"2019111808055659800_B42","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1172\/JCI112823","article-title":"Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells.","volume":"79","author":"White","year":"1987","journal-title":"J Clin Invest"},{"issue":"8","key":"2019111808055659800_B43","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.leukres.2007.12.015","article-title":"Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H.","volume":"32","author":"Huang","year":"2008","journal-title":"Leuk Res"},{"issue":"7","key":"2019111808055659800_B44","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1182\/blood-2009-10-246199","article-title":"Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.","volume":"116","author":"Balakrishnan","year":"2010","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/8\/2184\/1348090\/zh803411002184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/8\/2184\/1348090\/zh803411002184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T08:22:38Z","timestamp":1574065358000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/8\/2184\/29437\/In-vitro-efficacy-of-forodesine-and-nelarabine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,25]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-02-337840","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,25]]}}}